^
Association details:
| Biomarker: | BCR-ABL1 G250E |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Bosutinib…Contraindicated mutations...T315I, V299L, G250E, or F317L
